Drug Trial Radar · NCT04879043
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
78
Planned (sponsor's estimate)
Start
Feb 7, 2022
Primary completion
Mar 2028
Study completion Sep 2028
Sponsor
- Lead sponsor
- Heidelberg Pharma AGIndustry
- Sponsor type
- Industry
- First posted
- May 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.
Conditions
- Multiple Myeloma
- Plasma Cell Disorder
Interventions
HDP-101Drug
HDP-101 is available as lyophilized white powder for preparation of infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients who experience dose-limiting toxicity (DLT) during the first cycle of treatment - Part 1 as defined in Clinical Study ProtocolTime frame: Up to Day 21 (from first dose)
- Objective response rate (ORR)Time frame: Through study completion, an average of 1 year
Locations
24 sites in 5 countries. Site status is shown where the registry gives one.
Winship Cancer Institute of Emory University
Atlanta, Georgia · Recruiting
Norton Healthcare, Inc.
Louisville, Kentucky · Not yet recruiting
Nebraska Cancer Institute
Omaha, Nebraska · Recruiting
Mount Sinai, The Tisch Cancer Instutute
New York, New York · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Charité - Campus Benjamin Franklin Med. Klinik m.S. Hämatologie, Onkologie
Berlin, Germany · Withdrawn
Klinikum Chemnitz gGmbH, Klinik f. Innere Medizin III
Chemnitz, Germany · Withdrawn
Universitätsklinikum Köln
Cologne, Germany · Withdrawn
Asklepios Klinik Altona, Haematologie und internistische Onkologie
Hamburg, Germany · Withdrawn
Universitätsklinikum Heidelberg
Heidelberg, Germany · Active not recruiting
Universitätsklinikum Schleswig-Holstein
Kiel, Germany · Withdrawn
UKSH Campus Lübeck Klinik für Hämatologie und Onkologie
Lübeck, Germany · Active not recruiting
Universitätsklinikum Mainz
Mainz, Germany · Withdrawn
Semmelweis University, Belgyogyaszati es Onkologiai Klinika
Budapest, Hungary · Recruiting
National Institute of Oncology, Department of Oncological Internal Medicine
Budapest, Hungary · Withdrawn
Pécsi Tudományegyetem Klinikai Központ
Pécs, Hungary · Not yet recruiting
Pratia Onkologia Katowice
Katowice, Poland · Recruiting
Pratia Onkologia Kraków
Krakow, Poland · Recruiting
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi
Lodz, Poland · Withdrawn
Szpital Wojewodzki w Opolu
Opole, Poland · Withdrawn
AIDPORT Sp. zo.o.
Skórzewo, Poland · Recruiting
MICS Centrum Medyczne Torun
Torun, Poland · Recruiting
Arensia Clinics SRL
Bucharest, Romania · Recruiting
Oncology Institute Prof. Dr. Ion Chiricuta I.O.C.N.
Cluj-Napoca, Romania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.